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Abstract
Introduction Treating therapy-resistant patients with inherited
arrhythmia syndromes can be difficult and left cardiac sym-
pathetic denervation (LCSD) might be a viable alternative
treatment option. We provide an overview of the indications
and outcomes of LCSD in patients with inherited arrhythmia
syndromes in the only tertiary referral centre in the Nether-
lands where LCSD is conducted in these patients.
Methods This was a retrospective study, including all patients
with inherited arrhythmia syndromes who underwent LCSD
in our institution between 2005 and 2013. LCSD involved
ablation of the lower part of the left stellate ganglion and the
first four thoracic ganglia.
Results Seventeen patients, 12 long-QT syndrome (LQTS)
patients (71 %) and 5 catecholaminergic polymorphic ventric-
ular tachycardia (CPVT) patients (29 %), underwent LCSD.
Most patients (94 %) were referred because of therapy-
refractory cardiac events. In 87 % the annual cardiac event
rate decreased. However, after 2 years the probability of
complete cardiac event-free survival was 59 % in LQTS and
60 % in CPVT patients. Two patients (12 %) had major non-
reversible LCSD-related complications: one patient suffered
from a Harlequin face post-procedure and one severely affect-
ed LQT8 patient died the day after LCSD due to complica-
tions secondary to an arrhythmic storm during the procedure.
Conclusion LSCD for inherited arrhythmia syndromes,
which is applied on a relatively small scale in the Netherlands,
reduced the cardiac event rate in 87% of the high-risk patients
who had therapy-refractory cardiac events, while the rate of
major complications was low. Therefore, LSCD seems a
viable treatment for patients with inherited arrhythmia syn-
dromes without other options for therapy.
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Introduction
Primary inherited arrhythmia syndromes, such as long-QT
syndrome (LQTS) and catecholaminergic polymorphic ven-
tricular tachycardia (CPVT), are genetic cardiac diseases with-
out apparent structural heart disease that may cause cardiac
syncope and sudden cardiac death, mainly in young individ-
uals. These cardiac events are generally induced by physical
or emotional stress triggers [1–3]. Hence, β-blockers are
considered first-line therapy in symptomatic and asymptom-
atic patients in both conditions [4, 5]. In addition, an implant-
able cardiac defibrillator (ICD) is often used in patients who
continue to have ventricular arrhythmias despite β-blocker
therapy [5, 6]. However, ICDs do not prevent ventricular
arrhythmias and can even trigger catecholamine release, subse-
quently resulting in arrhythmic storms and even death [7]. Also
the cost of frequent shocks in terms of pain and fear is substan-
tial [8] and young patients with ICDs are more likely to expe-
rience device complications, including inappropriate shocks
and lead-related complications, over many years of use [9].
In 1971, Moss and McDonald [10] described left cardiac
sympathetic denervation (LCSD), which prevents norepi-
nephrine release in the heart, therefore raising the threshold
for ventricular fibrillation without reducing the heart rate or
impairing myocardial contractility [11]. In the last decade
LCSD has received renewed attention as a viable alternative
treatment for therapy-resistant LQTS and CPVT patients. A
significant protective effect of LCSD was demonstrated in
both symptomatic and asymptomatic LQTS and CPVT pa-
tients [12–16]. In the Netherlands, LCSD is applied on a small
scale and we hereby provide an overview of the indications
and outcomes of LCSD in patients with inherited arrhythmia




Patients who received LCSD in our hospital between 1 Novem-
ber 2005 and 1 February 2013 for LQTS or CPVTwere included
in this study. LQTS was defined according to the diagnostic
criteria described by Schwartz et al. [17] The QT interval was
assessed from lead II/V5 and corrected for heart rate using
Bazett’s formula. CPVT was diagnosed based on exercise-
induced bidirectional or polymorphic ventricular tachycardia
(VT) in the absence of structural cardiac disease and a putative
pathogenic mutation in a CPVT-causing gene [2].
All data available prior to and after the LCSD were retro-
spectively extracted from medical records. These included
demographic data, clinical data (initial presentation, age at
onset, family history of sudden cardiac death (SCD)
<60 years), genotype, ECG data, presence of ICD andmedical
therapy, incidence of cardiac events and indication for surgery.
Cardiac events were defined as cardiac syncope, aborted
cardiac arrest (ACA), appropriate ICD shocks or malignant
non-sustained ventricular tachycardias (NSVT). LSCD-
related data included procedure time, length of hospital stay
and postoperative complications. The surgery was considered
secondary prevention if the patient had a history of cardiac
events. The institutional review board of our institution
waived the requirement for informed consent.
Surgical procedure
In the first group of patients (n=6), the surgical procedure for
LCSD started with an incision at the base of the neck
(supraclavicular approach [18], performed by A.O., A.D.
and D.K.), which is an extrapleural approach without opening
the chest. The other patients underwent a video-assisted
thoracoscopic LCSD [19], except for one 2-month-old baby
who underwent denervation by thoracotomy (performed by
A.D. and D.K.). In both the supraclavicular and video-
assisted thoracoscopic approach, the lower part of the
stellate ganglion (preferably dissection along the ana-
tomical fusion between the upper and lower pole) was
removed together with the second and third thoracic
ganglia; the fourth ganglion was cauterised. Additional
visible nerve structures from the sympathetic ganglia
towards the heart were also cauterised. It provides ade-
quate cardiac denervation with no or minimal Horner’s
syndrome, because the upper half of the stellate gangli-
on is preserved.
Statistics
All data were analysed with SPSS (19.0 SPSS Inc, Chicago,
IL). Categorical data are displayed as percentage and com-
pared between groups using a χ2 test. Normally distributed
continuous data, tested for normality with the Shapiro-Wilk
test, were described as mean (standard deviation [SD]). Con-
tinuous data not normally distributed were expressed as me-
dian (interquartile range [IQR]) and compared between
groups using the Mann-Whitney U-test. Annual event rates
were calculated as the number of events per year of observa-
tion. Postoperative event-free survival was described by
Kaplan-Meier cumulative estimates. Confidence intervals for
the median number of episodes and the median annual event
rates were based on the method proposed by Bonett and Price
[20]. The patient who died a few days after LCSD was
removed from the denominator in the cardiac event anal-
ysis after LCSD, since follow-up was not possible. P-
values <0.05 were considered statistically significant.
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Results
Patient characteristics
From November 2005 to January 2013, 17 patients (12 LQTS
patients (71 %) and 5 CPVT patients (29 %)) had a LCSD
performed at our institution. Clinical characteristics of these
patients are summarised in Table 1. The mean age of the entire
study population at the time of LCSD was 19±14 years and
59 % were female. All patients were on β-blocking therapy
and three of the five CPVT patients had additionally taken
flecainide prior to LCSD. Eight patients (47 %), of whom
seven were diagnosed with LQTS, had already ICD implanted
by the time of the surgery and one LQTS patient received an
ICD 1 month after LCSD.
All CPVT patients had a mutation in the RyR2 gene, which
were classified as putatively pathogenic in four patients. One
patient (#2 in Fig. 1) had an unclassified variant in the RyR2
gene. Of the patients with LQTS, six (50 %) had a mutation in
the KCNH2 gene, and two patients (17 %) had LQTS type 1
based on a mutation in the KCNQ1 gene. One LQTS patient
(#11) was tested for all known LQTS genes, but no mutation
was found.
Indications
Sixteen patients (94 %) underwent LCSD after experiencing
cardiac events under adequate medical therapy (9 [53 %] VT/
VF, 5 [29 %] syncope and 2 [12 %] malignant NSVT), while
one patient (5.9 %) underwent LCSD for primary prevention
because of β-blocker intolerance. Figure 1 demonstrates the
event rate timing prior to LCSD.
LCSD procedure
Six (35 %) patients underwent LCSD using the
supraclavicular approach and in 10 patients (58 %) LCSD
was performed via a video-assisted thoracoscopic approach.
One 2-month-old baby underwent LCSD via thoracotomy
because a video-assisted thoracoscopic approach was not
deemed feasible. The median skin-to-skin time was 46 (IQR
39-61) minutes, with a median time of 40 (IQR 34–78)
minutes for the supraclavicular approach and 47 (IQR 43–
67) minutes for the thoracoscopic approach (p=0.33). The
median number of hospitalisation days after the procedure
was 3 (IQR 2–7) days. There was no difference in number
of hospitalisation days between the two surgical approaches
(supraclavicular approach 3 (IQR 3–23) days and
thoracoscopic approach 2 (IQR 2–4) days; p=0.13).
Major non-reversible complications of the LCSD were
reported in 2/17 (12 %) of the patients. One patient (5.9 %)
suffered from a postoperative Harlequin face. One severely
affected LQT8 patient (5.9 %; patient #6 in Fig. 1) with
multiple arrhythmic storms before LCSD died after the pro-
cedure, due to multi-organ failure secondary to bradycardias
followed by arrhythmic storms in combination with severe
electrolytic disturbances and hypoglycaemia during and after
the procedure. Minor complications of the LCSD, which
spontaneously resolved, were reported in four (24 %) addi-
tional patients: three of these patients (18 %), all treated using
the video-assisted thoracoscopic approach, were diagnosed
with a post-procedural pneumothorax and one patient
(5.9 %) had a transient postoperative Horner’s syndrome.
Cardiac events after LCSD
During a median follow-up of 34 (IQR 16–77) months, 7 out
of 15 (47 %) symptomatic patients did not experience any
occurrence of cardiac events after LCSD (Fig. 1). Cardiac
events continued in 8/15 (53 %) symptomatic patients
(Fig. 1 and Table 2). In one of these patients with recurrences,
an ICD shock occurred after a decrease in β-blocker dosage
and in two patients only asymptomatic NSVT persisted, while
they suffered from life-threatening cardiac syncope and ICD
shocks before LCSD. Additionally, one patient (#17), who
was diagnosed with LQT3 which overlapped with Brugada
syndrome, had recurrences of life-threatening cardiac events
after LCSD, but these events were mainly fever-related and
thus probably related to Brugada syndrome. Life-threatening
cardiac events persisted at a high(er) annual event rate after
LCSD in only one patient. This LQT2 patient (#12) experi-
enced multiple appropriate ICD shocks after LCSD during the
postpartum period. When analysing the video-assisted thorac-
ic surgery footage in retrospect, the removal of the lower part
of the stellate ganglion was insufficiently cranial. In general,
cardiac events on adequate medical therapy recurred in 0 out
of 2 LQT1 patients, three out of six LQT2 patients, two out of
two LQT3 patients (n=2/2), and two out of five of the CPVT
patients.
In total, in 13/15 symptomatic patients (87 %) the annual
cardiac event rate decreased importantly after LCSD. The
median number of cardiac events decreased from five (95 %
confidence interval [CI]: 0–22) to 0 (95 % CI: 0–3.5). The
median annual event rate decreased from 1.7 (95 % CI: 0–5.6)
to 0 (95 % CI: 0–1.0).
Kaplan-Meier estimates of postoperative cardiac event-free
survival in all patients and by disease are shown in Fig. 2.
Patients with LQTS had a 71% and 59% probability of event-
free survival at 1 and 2 years, respectively, while these rates
were 60 % after both 1 and 2 years in CPVT patients.
Discussion
Today, LCSD is increasingly recognised as a viable treatment
for therapy-resistant LQTS and CPVT patients [13–15]. Here
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Table 1 Patient characteristics
Total LQTS CPVT
Total number of patients 17 12 5
Female 10 (59 %) 7 (58 %) 3 (60 %)
Family history of sudden cardiac
death <60 years
5 (29 %) 2 (17 %) 3 (60 %)
Genotype
▪ KCNQ1 mutation (LQT1) 2 (12 %) 2 (17 %) 0
▪ KCNH2 mutation (LQT2) 6 (35 %) 6 (50 %) 0
▪ SCN5A mutation (LQT3) 2 (12 %) 2 (17 %) 0
▪ CACNA1C mutation (LQT8) 1 (5.9 %) 1 (8.3 %) 0
▪ LQTS of unknown type 1 (5.9 %) 1 (8.3 %) 0
▪ RyR2 mutation 5 (29 %) 0 5 (100 %)
Presentation
▪ Aborted cardiac arrest / VT in history 6 (35 %) 4 (33 %) 2 (40 %)
▪ Cardiac syncope 6 (35 %) 4 (33 %) 2 (40 %)
▪ Family history 4 (24 %) 3 (25 %) 1 (20 %)
▪ Medical evaluation, other 1 (5.9 %) 1 (8.3 %) 0
Age at first cardiac event (median) 11 (IQR 0–18) 12 (IQR 0–17) 10 (IQR 2–19)
Age at LCSD (mean) 19±14 20±16 17±4
Indication for LCSD
▪ Primary prevention 1 (5.9 %) 1 (8.3 %) 0
▪ Secondary prevention 16 (94 %) 11 (92 %) 5 (100 %)
Prior therapies
▪ β-blocker 17 (100 %) 12 (100 %) 5 (100 %)
▪ Mexiletine 2 (12 %) 2 (17 %) 0
▪ Flecainide 4 (24 %) 1 (8.3 %) 3 (60 %)
ICD 9 (53 %) 8 (67 %) 1 (20 %)
QTc
▪ Pre-LCSD (median) 460 (IQR 395–496) 477 (IQR 413–526) 390 (IQR 381–442)
▪ Post-LCSD (median) 450 (IQR 413–504) 459 (IQR 440–538) 402 (IQR 348–464)
CPVT catecholaminergic polymorphic ventricular tachycardia, ICD implantable cardiac defibrillator, IQR interquartile range, LCSD left cardiac
sympathetic denervation, LQTS long-QT syndrome
Fig. 1 Comparison of cardiac
events before and after LSCD
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we report the experience in the only tertiary referral centre in
the Netherlands for this treatment in 17 patients with inherited
arrhythmia syndromes. Most patients (94 %) were referred
because of therapy-refractory cardiac events. In 87 % of the
symptomatic patients, the annual cardiac event rate decreased.
However, after 2 years the probability of cardiac event-free
survival was 59% in LQTS and 60% in CPVT patients. There
were four patients (24 %) with minor reversible complications
who did not require any intervention, which is a similar num-
ber compared with other centres [14, 15, 21], and one patient
(5.9 %) with a non-reversible post-procedural Harlequin face.
Also, one LQT8 patient (5.9 %) died after the LCSD procedure
due to complications secondary to bradycardias followed by an
arrhythmic storm in combination with electrolytic disturbances
and hypoglycaemia during the procedure. An identical case
was reported by Schwartz et al. [12] in 1991, where a 3-year-
old female patient died early postoperatively with suspected
post-anaesthesia hypoxic distress (hypoglycaemia, respiratory
failure, complete heart block and asystole). This patient was
later identified as a LQT8 patient, and extreme caution should
be taken in this type of patients.
Success of LCSD
Our results are in agreement with previously published expe-
rience. Indeed, multiple studies have reported a significant
decrease of cardiac events in 90% of the symptomatic patients
with inherited arrhythmia syndromes after LCSD, although
approximately 40 % remained symptomatic [13–15, 19,
21–23]. The antiarrhythmic and antifibrillatory effects of
LCSD are attributed to the reduced release of norepinephrine
at the level of the ventricles [11]. This sympathetic blockade
prolongs ventricular refractoriness and increases the ventricu-
lar fibrillation threshold, resulting in the prevention or sup-
pression of triggered activity [11]. The denervation has a
highly specific antiarrhythmic effect, without reducing the
heart rate (which might be especially important for LQT3
patients) and without impairing myocardial contractility [11].
Additionally, because the denervation does not completely
eliminate catecholamine input to the heart, surgery does not
lead to hypersensitivity [11]. And lastly, re-innervation is not
Table 2 Patient characteristics of patients with cardiac events after LCSD while on adequate medical therapy
Patient
ID












2 Female CPVT 21 21 >100b 1b Exercise 383/423 ms
3 Male CPVT 3 15 >100 4 Exercise 390/402 ms
8 Female LQT2 16 35 >10 7b During rest, waking up or in the evening 460/441 ms
12 Female LQT2 16 19 3 >10b Sudden emotion/noise 533/439 ms
13 Male LQT3 Birth 0 >100 >50 Neonatal, during rest or suddenly 654/642 ms
15 Female LQT2 20 25 9 7 Sudden emotion/noise and postpartum period 506/503 ms
16 Female LQT2 12 21 5 1c During rest, waking up or suddenly 485/505 ms
17 Male LQT3 and BrS Birth 4 >50 >10 Neonatal, playing and during fever 535/352 ms
BrS Brugada syndrome, CPVT catecholaminergic polymorphic ventricular tachycardia, LCSD left cardiac sympathetic denervation, LQTS long-QT
syndrome
aUnder adequate medication
bOnly short non-sustained ventricular tachycardia (<10 complexes)
c Cardiac event (CE) after LCSD was after decrease in β-blocker dosage
Fig. 2 a Kaplan-Meier curves of event-free survival after LCSD: a all
patients and b by disease
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expected because the denervation is pre-ganglionic, which
makes it likely that the effects are durable [18]. However,
especially in highly symptomatic patients with inherited ar-
rhythmia syndromes, LCSD has so far been advocated merely
as an adjuvant therapy besides β-blockers (in LQTS and
CPVT) or flecainide (in CPVT), as also demonstrated by the
breakthrough cardiac event of patient #16 after lowering the
β-blocker dosage. Indeed, ICDs should still be considered in
patients at high risk for SCD.
Recently, percutaneous renal sympathetic denervation has
emerged as a therapeutic option for patients with hyperactivity
of the sympathetic system such as therapy-resistant hyperten-
sion [24]. Additionally, in animal models renal denervation
suppressed ventricular arrhythmias [25]. These findings support
the hypothesis that renal denervation might also be useful in
reducing sympathetic activity in highly symptomatic patients
with inherited arrhythmia syndromes and thereby reducing
cardiac event rate, although this needs to be studied in the future.
Response to LCSD among the different genotypes
Although there was a significant decrease in cardiac events in
most patients, half of the patients remained symptomatic.
Post-LCSD cardiac events recurred in 3/6 of the LQT2 pa-
tients, 2/2 of the LQT3 patients, and 2/5 of the CPVT patients,
while none of the LQT1 patients had events. The number of
patients is too small to draw any meaningful conclusions, but
the various results among the different genotypes are in agree-
ment with the underlying pathophysiological mechanism.
During gradual progressive sympathetic activation (such as
exercise), the reduced, catecholamine-sensitive, slow delayed
rectifier potassium current (IKs) in LQT1 patients prevents the
necessary QT adaptation, causing a risk for triggered activity
and ventricular arrhythmias [26, 27]. Therefore, removing the
sympathetic activation of the heart with LCSD appeared to be
very successful in LQT1 patients [15].
On the other hand, cardiac events in LQT2 patients are often
triggered by a sudden heart rate acceleration, such as during a
loud noise or surprising emotion [28]. In LQT2 patients with a
reduced rapid delayed rectifier potassium current (IKr), possible
extrasystoles triggered by these triggers result in a markedly
pause-dependent prolongation of the action potential duration
of the following heart beat and attendant risk of early
afterdepolarisations [27, 29]. Sudden heart rate increment is
caused by vagal withdrawal rather than sympathetic activation
[30] and this might explain that removal of the sympathetic
activation by LCSD is not so successful in all LQT2 patients.
Also the occurrence of extrasystoles might not be prevented.
In both LQT3 patients, the number of cardiac events de-
creased, but the effect of LCSDwas not complete. Also, failure
of complete LCSD success in CPVT may be attributed to the
fact that only the local, cardiac, release of catecholamines is
blocked. Systemic release of catecholamines is still pertinent
and may be sufficient to elicit triggered arrhythmias during
physical exercise, despite β-blockade and flecainide therapy.
Furthermore, one CPVT patient (#2) with recurrent events
carries an unclassified variant in the RyR2 gene, which might
indicate that the diagnosis CPVT might not be correct.
Although the success of LCSD was not complete among
the different genotypes, the number of events decreased in
almost all patients (87 %), thus significantly improving the
quality of life of the patients and their families. Therefore,
LCSD continues to be worthwhile in highly symptomatic
patients with primary arrhythmias.
Limitations
This is retrospective study with a small number of patients,
secondary to the rare prevalence of therapy-resistant LQTS
and CPVT patients. Due to the retrospective nature, a quanti-
tative marker of arrhythmia burden has been difficult to ex-
press in statistically comparable data due to the large variabil-
ity in presenting symptoms, resulting in a wide definition of
cardiac events. Also, in patients without an ICD, the lack of
continuous heart rate monitoring could have resulted in an
underestimation of cardiac events, especially NSVT. Howev-
er, cardiac event monitoring before and after LCSD was
identical in all patients except for one LQT patient who
received an ICD 1 month after LCSD.
Conclusion
LSCD for inherited arrhythmia syndromes, although applied
on a small scale in the Netherlands, reduced the cardiac event
rate in 87 % of the high-risk patients who had therapy refrac-
tory cardiac events. Although one severely affected LQT8
patient died secondary to surgery-related issues, LSCD seems
a viable treatment for patients with inherited arrhythmia syn-
dromes without other options for therapy.
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